Atopic Conjunctivitis in Children: Influence of Treatment with Topical Cyclosporin 0.05% in the Quality of Life
DOI:
https://doi.org/10.29328/journal.aaai.1001001Keywords:
Allergy, Atopic, Conjunctivitis, Children, Cyclosporine 0.05%, Quality of lifeAbstract
Introduction: Forty-six per cent children have allergic rhinoconjunctivitis (Allergologica 2005). Working hypothesis: Ocular topical cyclosporine improves the quality of life for these patients. Material, methods, design: 2-year prospective study (2015-16), 40 patients with topical corticosteroids without improvement, followed 20 and 20 switched to corticosteroids cyclosporine 0.05%. Interview with Quality of Life Questionnaire in Children with rhinoconjunctivitis (PRQLQ) before and at the end of treatment. Mean age of 10.3 years with 60% male-40% female. Treatments were applied from January to March. There were 15 questions divided into two blocks. Children responded using a card with responses rated from zero (not bothered at all) to 6 (quite upset). Results: Before the 100% reported that, the itching was very bothersome. In the group of 40 children, 80% showed symptoms of epiphora and 60% showed symptoms of ocular inflammation. 100% complained of significant discomfort in rubbing their eyes, 30% did not like to take medications. Headaches affected 20%. 100% stated that they cannot play normally. 80% showed decreased concentration in class. Continuing with corticosteroids did not show statistically significant changes. Patients with cyclosporine improved the results by 3 points, with decreased itching, tearing, swelling, pain, eye rubbing, medication and headaches. In the 2nd questionnaire there was limited variation in the results related to fatigue, malaise, and irritability but with substantially improved balance of sleep, insomnia and concentration at school. Conclusion: Cyclosporine A is a cyclic polypeptide calcineurin inhibitor developed from the fungus Tolypocladium inflatum. The first dilution was 2% but it is currently used at a dilution of 0.05% and recent publications suggest nanosuspensions. Our study showed improvement in parameters related to symptoms, especially itching and lower improvement of psychological aspects, this achieves a better quality of life for children and more willingness to adhere to the treatment.References
Sociedad Española de Alergología e Inmunología Clínica. Alergologica 2005: Factores epidemiológicos, clínicos y socioeconómicos de las enfermedades alérgicas en España. Madrid: Luzán 5 S.A. de Ediciones. 2006.
Kari O, Saari KM. Updates in the treatment of occular allergies. J Asthma Allergy. 2010; 3: 149-158. Ref.: https://goo.gl/EAAhex
Stoppel J. Alergia ocular. Rev Med Clin Condes. 2010; 21: 875-882. Ref.: https://goo.gl/ySZI1M
Shii D, Nakagawa S, Yoshimi M, Katsuta O, Oda T, et al. Symptoms in Late Phase and Delayed-Type Reactions in Allergic Conjunctivitis Models. Biol Pharm Bull. 2010; 33: 1314-1318. Ref.: https://goo.gl/tYLhfq
BenEzra D, Peer J, Brodsky M, Cohen E. Cyclosporine eye drops for the treatment of severe vernal keratoconjunctivitis. Am J Opthalmol. 1986; 101: 278-282. Ref.: https://goo.gl/xPFJwP
Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Opthalmol. 1990; 110: 641-645. Ref.: https://goo.gl/EYAQIz
Kaan G, Ozden O. Therapeutic use of topical cyclosporine. Ann Opthalmol. 1993; 25: 182-186. Ref.: https://goo.gl/EXUx6F
Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Opthalmology. 1991; 98: 1679-1684. Ref.: https://goo.gl/EesFfJ
Gupta V, Sahn PK. Topical cyclosporine A in the management of vernal keratoconjunctivitis. Eye (London). 2001; 15: 39-41. Ref.: https://goo.gl/oBDasp
Spadavechia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr allergy Inmunol. 2006; 17: 527-532. Ref.: https://goo.gl/GxLsVJ
Duque B, Restrepo CA. Tratamiento de la conjuntivitis alérgica crónica con ciclosporina tópica. Unidad médica CES 1991-1992. Revista CES Mediana. 1992; 6: 2. Ref.: https://goo.gl/Rpn8im
Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporine A 0.05% eyedrops. Cornea. 2007; 26: 1035-1038. Ref.: https://goo.gl/0zr4G9
Kim JH, Woo JS, Dug HS, Don HH, Gon CH. Development of a novel ophthalmic cyclosporine A-loaded nanosuspension using top-down media milling methods. Pharmazie. 2011; 66: 491-495. Ref.: https://goo.gl/f9Of72
Juniper EF, Howland WC, Roberts NB, Thompson AK, King DR. Measuring quality of live in children with rhinoconjunctivitis. J Allergy Clin Inmunol. 1998; 101: 163-170. Ref.: https://goo.gl/4bAHDe
Tesse R, Spadavecchia L, Fanelli P, Rizzo G, Procoli U, et al. Treatment of several vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol. 2010; 21: 330-335. Ref.: https://goo.gl/GyNs3P
Akova YA, Rodriguez A, Foster CS. A randomised trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ocular Immun Inflamm. 1994; 2: 125-144.
Pucci N, Caputo R, Mori F, De Libero C, Di Grande L, et al. Long-tern safety and efficacy of topical cyclosporine in 156 children with vernal keratoconcjuntivitis. Int J Immunopathol Pharmacol. 2010; 23: 865-871. Ref.: https://goo.gl/Hj1XzT
Spadavecchia L, Fanelli P, Tesse R, Rizzo G, Procoli U, et al. Prognosis and treatment of vernal keratoconjunctivitis in pediatric age: pilot study on 197 patients. Minerva Pediatr. 2010; 62: 239-244. Ref.: https://goo.gl/scrQdR
Keklikci U, Sevda Soker I, Yildirim Sakalar B, Kaan Unlu, Selver Ozekinci, et al. Efficacy of topical cyclosporine A 0.05% in conjunctival impression cytology specimens and clinical findings os fevere vernal keratoconjunctivitis in children. Jpn J Ophthalmolol. 2008; 52: 357-362. Ref.: https://goo.gl/9LReSj
Hingorani M, Moodaley L, Virginia Calder L, Roger Buckley J, Lightman S. A randomised, placebo-controlled trial of topical cyclosporine A in steroid-dependent atopic keratoconcjuntivitis. Ophthalmology. 1998; 105: 1715-1720. Ref.: https://goo.gl/ortAs4
Tesse R, Fanelli P, Rizzo G, Spadavecchia L, Procoli U, et al. Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children. Pediatr Allergy Immunol. 2010; 21: 330-335. Ref.: https://goo.gl/3CNyCk
Daniell M, Constantinuo M, Vu H T, Tayleo HR. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophtalmol. 2006; 90: 461-464. Ref.: https://goo.gl/05P6ts
Published
How to Cite
License
Copyright (c) 2017 Sánchez Salguero CA et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This work is licensed under a Creative Commons Attribution 4.0 International License.
